BIOMAT Database Logo BIOMAT Database Logo

Synthesis of some novel quinazolin-4(3H)-one hybrid molecules as potent urease inhibitors. 2018

Emre Menteşe, and Gülay Akyüz, and Fatih Yılmaz, and Nimet Baltaş, and Mustafa Emirik
Faculty of Arts and Sciences, Department of Chemistry, Recep Tayyip Erdogan University, Rize, Turkey.

A new series of quinazolinone hybrid molecules containing coumarin, furan, 1,2,4-triazole and 1,2,4-thiadiazole rings was designed, synthesized, and screened for their urease inhibition activities. All newly synthesized compounds showed outstanding urease inhibitory potentials with IC50 values ranging between 1.26 ± 0.07 and 7.35 ± 0.31 μg/mL. Among the series, coumarin derivatives (10a-d) exhibited the best inhibitory effect against urease in the range of IC50  = 1.26 ± 0.07 to 1.82 ± 0.10 μg/mL, when compared to standard urease inhibitors such as acetohydroxamic acid and thiourea (IC50  = 21.05 ± 0.96 and 15.08 ± 0.71 μg/mL, respectively). Molecular docking studies were also performed to analyze the binding mode of compound 10b, and supported the experimental results.

UI MeSH Term Description Entries
D007887 Fabaceae The large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of "beans" belong to this family. Afzelia,Amorpha,Andira,Baptisia,Callerya,Ceratonia,Clathrotropis,Colophospermum,Copaifera,Delonix,Euchresta,Guibourtia,Legumes,Machaerium,Pithecolobium,Stryphnodendron,Leguminosae,Pea Family,Pithecellobium,Tachigalia,Families, Pea,Family, Pea,Legume,Pea Families
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014510 Urease An enzyme that catalyzes the conversion of urea and water to carbon dioxide and ammonia. EC 3.5.1.5. Phytourease,Urea Amidohydrolase,Amidohydrolase, Urea
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D052999 Quinazolinones Chemicals with two conjoined aromatic rings incorporating two nitrogen atoms and one of the carbons oxidized with a keto oxygen. Quinazolinedione,Quinazolinone,Quinazolinediones
D062105 Molecular Docking Simulation A computer simulation technique that is used to model the interaction between two molecules. Typically the docking simulation measures the interactions of a small molecule or ligand with a part of a larger molecule such as a protein. Molecular Docking,Molecular Docking Simulations,Molecular Docking Analysis,Analysis, Molecular Docking,Docking Analysis, Molecular,Docking Simulation, Molecular,Docking, Molecular,Molecular Docking Analyses,Molecular Dockings,Simulation, Molecular Docking
D020128 Inhibitory Concentration 50 The concentration of a compound needed to reduce population growth of organisms, including eukaryotic cells, by 50% in vitro. Though often expressed to denote in vitro antibacterial activity, it is also used as a benchmark for cytotoxicity to eukaryotic cells in culture. IC50,Concentration 50, Inhibitory

Related Publications

Emre Menteşe, and Gülay Akyüz, and Fatih Yılmaz, and Nimet Baltaş, and Mustafa Emirik
Synthesis and anticonvulsant activity of some quinazolin-4-(3H)-one derivatives.
January 2008, Molecules (Basel, Switzerland),
Emre Menteşe, and Gülay Akyüz, and Fatih Yılmaz, and Nimet Baltaş, and Mustafa Emirik
Synthesis and bioactivities evaluation of quinazolin-4(3H)-one derivatives as α-glucosidase inhibitors.
November 2022, BMC chemistry,
Emre Menteşe, and Gülay Akyüz, and Fatih Yılmaz, and Nimet Baltaş, and Mustafa Emirik
Design and synthesis of novel quinazolin-4(1H)-one derivatives as potent and selective inhibitors targeting AKR1B1.
April 2023, Archiv der Pharmazie,
Emre Menteşe, and Gülay Akyüz, and Fatih Yılmaz, and Nimet Baltaş, and Mustafa Emirik
Novel quinazolin-4(3H)-one/Schiff base hybrids as antiproliferative and phosphodiesterase 4 inhibitors: design, synthesis, and docking studies.
September 2014, Archiv der Pharmazie,
Emre Menteşe, and Gülay Akyüz, and Fatih Yılmaz, and Nimet Baltaş, and Mustafa Emirik
Synthesis and antihypertensive activity of novel quinazolin-4(3H)-one derivatives.
January 2014, Central nervous system agents in medicinal chemistry,
Emre Menteşe, and Gülay Akyüz, and Fatih Yılmaz, and Nimet Baltaş, and Mustafa Emirik
Design, synthesis, and pharmacological characterization of some 2-substituted-3-phenyl-quinazolin-4(3H)-one derivatives as phosphodiesterase inhibitors.
September 2021, Archiv der Pharmazie,
Emre Menteşe, and Gülay Akyüz, and Fatih Yılmaz, and Nimet Baltaş, and Mustafa Emirik
Discovery of quinazolin-4(3H)-one derivatives as novel AChE inhibitors with anti-inflammatory activities.
June 2023, European journal of medicinal chemistry,
Emre Menteşe, and Gülay Akyüz, and Fatih Yılmaz, and Nimet Baltaş, and Mustafa Emirik
Exploring new quinazolin-4(3H)-one derivatives as CDK2 inhibitors: Design, synthesis, and anticancer evaluation.
April 2024, Drug development research,
Emre Menteşe, and Gülay Akyüz, and Fatih Yılmaz, and Nimet Baltaş, and Mustafa Emirik
Design, synthesis, biological evaluation and structure-activity relationship study of quinazolin-4(3H)-one derivatives as novel USP7 inhibitors.
April 2021, European journal of medicinal chemistry,
Emre Menteşe, and Gülay Akyüz, and Fatih Yılmaz, and Nimet Baltaş, and Mustafa Emirik
Novel acetic acid derivatives containing quinazolin-4(3H)-one ring: Synthesis, in vitro, and in silico evaluation of potent aldose reductase inhibitors.
April 2023, Drug development research,
Copied contents to your clipboard!